Citius Pharmaceuticals, Inc. (NasdaqCM: CTXR)
Health Care · Pharmaceuticals · US
$0.50
-6.06% today · -61.6% 1Y
Citius Pharmaceuticals, Inc. (NasdaqCM: CTXR) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $13.71M and employs 23 people.
Over the last twelve months the share price has lost 61.6%, trading between 0.47 and 2.19.
Tweenvest scores Citius Pharmaceuticals, Inc. across four factors: quality 35/100, value 56/100. Its strongest factor is value.
CTXR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $13.71M
- Revenue (TTM)
- $7.11M
- P/E
- —
- EPS
- -2.12
- Dividend yield
- —
- Beta (5Y)
- 1.00
- 52-week high
- $2.19
- 52-week low
- $0.47
- Avg volume (3M)
- —
- Shares outstanding
- 27.45M
- Employees
- 23
- Next earnings
- —
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
- ISIN
- US17322U3068
- Founded
- 2007
- Listed since
- Oct 2, 2014
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Biotika a.s.BSSE: 1BSL01AE | $13.81M | €— | — |
| Yi Po International Holding LimitedOTCPK: YBZN | $13.77M | $— | — |
| Tvardi Therapeutics, Inc.NasdaqCM: TVRD | $13.74M | $1.03 | -10.43% |
| WooGene B&G Co., LtdKOSDAQ: A018620 | $13.72M | ₩2,660.00 | -0.19% |
| Lactose (India) LimitedBSE: 524202 | $13.52M | Rs103.95 | -1.38% |
| PT Phapros TbkIDX: PEHA | $13.52M | Rp288.00 | +2.86% |
| Klaria Pharma Holding AB (publ.)OM: KLAR | $13.36M | Skr0.54 | -8.12% |
| Ayr Wellness Inc.CNSX: AYR.A | $13.21M | CA$— | — |
Figures last refreshed Oct 11, 2026.